Open Accesstocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case)
Author(s) -
Д. Д. Авдошина,
Andrey Dyachkov,
Д. А. Гусев
Publication year - 2020
Publication title -
žurnal infektologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.185
H-Index - 5
eISSN - 2499-9865
pISSN - 2072-6732
DOI - 10.22625/2072-6732-2020-12-3-90-93
Subject(s) - tocilizumab , medicine , covid-19 , monoclonal antibody , immunology , clinical trial , recombinant dna , infectious disease (medical specialty) , disease , antibody , virology , biology , biochemistry , gene
Improving the approaches to treating COVID-19 infection opens up the possibility for using previously known groups of drugs that demonstrate their effectiveness in the pathogenetic treatment of this disease. Significant clinical experience in the field of treatment of COVID-19 have been accumulated in Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia. The case study demonstrates the timeliness and effectiveness of anticytokine therapy with COVID-19, the possibility of using a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (IL-6) (tocilizumab).